CL2012002080A1 - A combination comprising (4r, 12as) -n- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2h-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-b] [1,3] -oxazin-9-carboxamide (gsk1349572) and one or more of the group: abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of hiv. - Google Patents

A combination comprising (4r, 12as) -n- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2h-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-b] [1,3] -oxazin-9-carboxamide (gsk1349572) and one or more of the group: abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of hiv.

Info

Publication number
CL2012002080A1
CL2012002080A1 CL2012002080A CL2012002080A CL2012002080A1 CL 2012002080 A1 CL2012002080 A1 CL 2012002080A1 CL 2012002080 A CL2012002080 A CL 2012002080A CL 2012002080 A CL2012002080 A CL 2012002080A CL 2012002080 A1 CL2012002080 A1 CL 2012002080A1
Authority
CL
Chile
Prior art keywords
methyl
gsk1349572
pyrazino
lopinavir
abacavir
Prior art date
Application number
CL2012002080A
Other languages
Spanish (es)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012002080(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CL2012002080A1 publication Critical patent/CL2012002080A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Una combinación que comprende (4R,12aS)-N-[2,4-fluoro-fenil)-metil]-3,4,6,8,12,12A-hexahidro-7-hidroxi-4-metil-6,8-dioxo-2H-pirido-{1',2':4,5]-pirazino-[2,1-B][1,3]-oxazin-9-carboxamida (GSK1349572) y uno o más del grupo: Abacavir, efavirenz y lopinavir, adicionalmente puede contener lamivudina, útil para el tratamiento del VIH.A combination comprising (4R, 12aS) -N- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12A-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2H-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-B] [1,3] -oxazin-9-carboxamide (GSK1349572) and one or more of the group: Abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of HIV.

CL2012002080A 2010-01-27 2012-07-26 A combination comprising (4r, 12as) -n- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2h-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-b] [1,3] -oxazin-9-carboxamide (gsk1349572) and one or more of the group: abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of hiv. CL2012002080A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
CL2012002080A1 true CL2012002080A1 (en) 2012-11-30

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002080A CL2012002080A1 (en) 2010-01-27 2012-07-26 A combination comprising (4r, 12as) -n- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2h-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-b] [1,3] -oxazin-9-carboxamide (gsk1349572) and one or more of the group: abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of hiv.

Country Status (45)

Country Link
US (12) US20120295898A1 (en)
EP (6) EP3494972B1 (en)
JP (8) JP2013518107A (en)
KR (4) KR101964923B1 (en)
CN (2) CN102791129B (en)
AP (1) AP3551A (en)
AU (1) AU2011209788C1 (en)
BR (1) BR112012018670A2 (en)
CA (4) CA2967453C (en)
CL (1) CL2012002080A1 (en)
CO (1) CO6602152A2 (en)
CR (1) CR20120423A (en)
CY (4) CY1116509T1 (en)
DK (4) DK3127542T3 (en)
DO (2) DOP2012000205A (en)
EA (4) EA037601B1 (en)
EC (1) ECSP12012106A (en)
ES (4) ES2688925T3 (en)
FI (2) FI3494972T3 (en)
FR (2) FR18C1043I2 (en)
HK (3) HK1209629A1 (en)
HR (4) HRP20240168T1 (en)
HU (6) HUE040554T2 (en)
IL (5) IL221007A (en)
LT (4) LT2932970T (en)
LU (1) LUC00090I2 (en)
MA (1) MA34002B1 (en)
ME (2) ME02182B (en)
MX (4) MX356891B (en)
MY (1) MY188334A (en)
NO (2) NO2932970T3 (en)
NZ (4) NZ601319A (en)
PE (2) PE20121524A1 (en)
PH (2) PH12016500195A1 (en)
PL (4) PL3127542T3 (en)
PT (4) PT3494972T (en)
RS (4) RS65183B1 (en)
SG (3) SG182614A1 (en)
SI (4) SI3127542T1 (en)
SM (1) SMT201500177B (en)
TN (1) TN2012000376A1 (en)
TR (1) TR201807704T4 (en)
UA (1) UA105556C2 (en)
WO (1) WO2011094150A1 (en)
ZA (1) ZA201205586B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011209788C1 (en) 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy
RU2648457C2 (en) 2012-10-23 2018-03-26 Сипла Лимитед Pharmaceutical antiretroviral composition
MX357940B (en) 2012-12-21 2018-07-31 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use.
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
CA2897137A1 (en) * 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (en) 2013-07-12 2018-07-21
SI3252058T1 (en) 2013-07-12 2021-03-31 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
MD4794B1 (en) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Substituted quinolizine derivatives useful as HIV integrase inhibitors
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (en) 2014-06-20 2018-06-23
CA2956662A1 (en) 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
TWI738321B (en) 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP3736274A1 (en) 2015-04-02 2020-11-11 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029225A1 (en) * 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
MX2020000790A (en) 2017-07-21 2020-11-11 Viiv Healthcare Co Regimens for treating hib infections and aids.
JP2020528413A (en) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Regimen for treating HIV infection and AIDS
WO2019074826A2 (en) * 2017-10-13 2019-04-18 Viiv Healthcare Company Bi-layer pharmaceutical tablet formulation
TWI745900B (en) 2019-03-22 2021-11-11 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20230270677A1 (en) * 2020-01-09 2023-08-31 University Of Washington Long-acting therapeutic agent combinations and methods thereof
PE20221569A1 (en) 2020-02-24 2022-10-06 Gilead Sciences Inc TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS
ES2968058T3 (en) 2021-01-19 2024-05-07 Gilead Sciences Inc Substituted pyridotriazine compounds and uses thereof
AU2023225805A1 (en) * 2022-02-28 2024-10-17 Jericho Sciences, Llc Methods for viral infections
TWI843506B (en) 2022-04-06 2024-05-21 美商基利科學股份有限公司 Bridged tricyclic carbamoylpyridone compounds and uses thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5665720A (en) 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (en) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Method for treatment of retrovirus infections
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
WO1999048371A1 (en) 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (en) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
PL211544B1 (en) 2000-01-31 2012-05-31 Cook Biotech Inc Heart valve device containing set of valve stent
EE05400B1 (en) 2001-04-10 2011-04-15 Pfizer Inc. Prazole derivatives, pharmaceutical compositions containing them or their pharmaceutically acceptable salts, solvates or derivatives, their use and methods for their preparation
JO3429B1 (en) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidines derivatives
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AR040242A1 (en) * 2002-06-04 2005-03-23 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS
DE60303131T2 (en) 2002-06-27 2006-07-20 Medivir Ab SYNERGISTIC INTERACTION OF ABACAVIR AND ALOVUDIN
AU2004206827A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1720856B1 (en) * 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
JP4285353B2 (en) 2004-03-05 2009-06-24 清水建設株式会社 Evaluation method of chemical emission
AU2005249363A1 (en) * 2004-04-14 2005-12-15 Zhenhong R. Cai Phosphonate analogs of HIV integrase inhibitor compounds
US8633219B2 (en) 2004-05-21 2014-01-21 Japan Tobacco Inc. Combination therapy
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006024024A2 (en) 2004-08-23 2006-03-02 Teva Pharmaceutical Industries Ltd. Solid and crystalline ibandronate sodium and processes for preparation thereof
PL1632232T6 (en) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile
SG155939A1 (en) 2004-09-17 2009-10-29 Idenix Pharmaceuticals Inc Phosphoindoles as hiv inhibitors
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp Chemical compounds
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
DK2465580T3 (en) * 2005-04-28 2014-03-10 Viiv Healthcare Co POLYCYCLIC CARBAMOYL PYRIDONE DERIVATIVES WITH HIV INTEGRASE INHIBITIVE ACTIVITY
US20080280849A1 (en) 2005-06-01 2008-11-13 Herve Leh Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents
UA101141C2 (en) * 2005-12-30 2013-03-11 Гилиад Сайенсиз, Инк. Methods for improving the pharmacokinetics of hiv integrase inhibitors
SG170796A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Us Methods for improving the pharmacokinetics of hiv integrase inhibitors
EA014914B1 (en) * 2006-01-20 2011-02-28 Тиботек Фармасьютикалз Лтд. Long term treatment of hiv infection
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
WO2008011117A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Antiviral protease inhibitors
EA016267B1 (en) 2006-09-29 2012-03-30 Айденикс Фармасьютикалз, Инк. Enantiomerically pure phosphoindoles as hiv inhibitors
LT2487162T (en) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
KR20100041798A (en) 2007-06-29 2010-04-22 한국화학연구원 Novel hiv reverse transcriptase inhibitors
JP2010532350A (en) 2007-06-29 2010-10-07 コレア リサーチ インスティテュート オブ ケミカル テクノロジー Novel HIV reverse transcriptase inhibitor
US8088770B2 (en) 2007-07-06 2012-01-03 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
SI2175857T1 (en) * 2007-07-12 2014-01-31 Janssen R&D Ireland Crystalline form of (e) 4-ss4-ss4-(2-cyanoethenyl)-2,6-dimethylphenylcaminoc-2-pyrimidinylcaminocbenzonitrile
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
EP2217573A4 (en) 2007-11-01 2011-08-31 Uab Research Foundation Treating and preventing viral infections
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
AU2008342537A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
AU2008342536A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel C-21-keto lupane derivatives preparation and use thereof
AU2008346823B2 (en) 2008-01-04 2015-03-12 Gilead Sciences, Inc. Inhibitors of cytochrome P450
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
SI2320908T1 (en) * 2008-07-25 2014-05-30 Viiv Healthcare Company Dolutegravir Prodrugs
EP2376080B1 (en) * 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
ES2964383T3 (en) * 2008-12-11 2024-04-05 Viiv Healthcare Co Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
AU2011209788C1 (en) 2010-01-27 2014-08-28 Viiv Healthcare Company Antiviral therapy
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (en) 2010-06-17 2018-01-30 富津世生物技术有限公司 Compound, composition and application method as antiviral drugs
CN103781479A (en) 2011-04-01 2014-05-07 医药公司 Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
KR20170078868A (en) 2017-07-07
DK3127542T3 (en) 2018-11-12
JP2023085431A (en) 2023-06-20
SG10201707183TA (en) 2017-10-30
NO2018036I1 (en) 2018-10-15
TN2012000376A1 (en) 2014-01-30
US20160199379A1 (en) 2016-07-14
EP3494972A1 (en) 2019-06-12
EP3351249A1 (en) 2018-07-25
US20170281636A1 (en) 2017-10-05
IL267658A (en) 2019-08-29
HUE037812T2 (en) 2018-09-28
AP3551A (en) 2016-01-18
SMT201500177B (en) 2015-09-07
HK1209629A1 (en) 2016-04-08
PL3127542T3 (en) 2019-03-29
HK1250335A1 (en) 2018-12-14
US20170119777A1 (en) 2017-05-04
LTC2932970I2 (en) 2022-04-25
JP2019167371A (en) 2019-10-03
LT2932970T (en) 2018-06-25
CR20120423A (en) 2012-11-22
NZ627826A (en) 2016-01-29
EA201690872A3 (en) 2016-12-30
BR112012018670A2 (en) 2018-02-06
NO2932970T3 (en) 2018-08-18
ES2688925T3 (en) 2018-11-07
IL281959B (en) 2021-12-01
CY1121040T1 (en) 2019-12-11
JP6268386B2 (en) 2018-01-31
ME02182B (en) 2015-10-20
CA3060290C (en) 2022-07-12
AU2011209788B2 (en) 2014-02-06
HRP20181531T1 (en) 2018-11-16
CA3003988A1 (en) 2011-08-04
MX2012008774A (en) 2012-08-17
AP2012006445A0 (en) 2012-08-31
PT3494972T (en) 2024-02-12
CN105311033B (en) 2019-05-07
US20180098992A1 (en) 2018-04-12
US20150238496A1 (en) 2015-08-27
EP3127542A1 (en) 2017-02-08
IL281959A (en) 2021-05-31
EP2531027A1 (en) 2012-12-12
KR101830715B1 (en) 2018-04-04
CY2018029I1 (en) 2019-07-10
CN102791129B (en) 2015-09-30
CY2018029I2 (en) 2019-07-10
US20200230147A1 (en) 2020-07-23
HK1179522A1 (en) 2013-10-04
KR20120128640A (en) 2012-11-27
PT2531027E (en) 2015-09-16
HUE040554T2 (en) 2019-03-28
JP2017008087A (en) 2017-01-12
CN102791129A (en) 2012-11-21
EP2531027B1 (en) 2015-05-06
MY188334A (en) 2021-11-30
HUE065569T2 (en) 2024-06-28
KR20180078358A (en) 2018-07-09
KR101964923B1 (en) 2019-04-02
LT3127542T (en) 2018-11-26
IL257267A (en) 2018-03-29
EA201892277A1 (en) 2019-03-29
LUC00090I2 (en) 2019-01-08
FIC20240016I1 (en) 2024-05-31
US20170216284A1 (en) 2017-08-03
JP2018127473A (en) 2018-08-16
PE20160180A1 (en) 2016-05-04
ZA201205586B (en) 2014-01-29
EA037601B1 (en) 2021-04-20
US10426780B2 (en) 2019-10-01
FR18C1043I1 (en) 2018-11-30
LTPA2018013I1 (en) 2018-11-12
ES2670811T3 (en) 2018-06-01
AU2011209788A1 (en) 2012-08-16
PL3494972T3 (en) 2024-05-27
SI3494972T1 (en) 2024-03-29
JP2013518107A (en) 2013-05-20
IL221007A0 (en) 2012-09-24
ES2969969T3 (en) 2024-05-23
EP4316599A2 (en) 2024-02-07
DK2932970T3 (en) 2018-05-28
HRP20150770T1 (en) 2015-08-28
IL267658B (en) 2021-04-29
FR24C1024I1 (en) 2024-07-26
IL257267B (en) 2019-08-29
JP2016145204A (en) 2016-08-12
SG10201509476RA (en) 2015-12-30
PL2932970T3 (en) 2018-08-31
NZ627827A (en) 2016-02-26
SI2932970T1 (en) 2018-07-31
EP4316599A3 (en) 2024-04-10
EA202190473A2 (en) 2021-06-30
EP2531027A4 (en) 2013-07-03
PT2932970T (en) 2018-06-08
AU2011209788C1 (en) 2014-08-28
MX356891B (en) 2018-06-19
US11234985B2 (en) 2022-02-01
PL2531027T3 (en) 2016-01-29
NZ627824A (en) 2016-02-26
DK3494972T3 (en) 2024-01-29
CA2787691C (en) 2018-07-17
ECSP12012106A (en) 2013-05-31
JP2022071126A (en) 2022-05-13
DOP2012000205A (en) 2012-10-15
WO2011094150A1 (en) 2011-08-04
EP2932970B1 (en) 2018-03-21
HUS1800042I1 (en) 2018-11-28
RS54123B1 (en) 2015-12-31
CA3060290A1 (en) 2011-08-04
SI3127542T1 (en) 2018-11-30
EA032868B1 (en) 2019-07-31
ES2543066T3 (en) 2015-08-14
HRP20240168T1 (en) 2024-04-26
IL221007A (en) 2016-06-30
MX367937B (en) 2019-09-12
SI2531027T1 (en) 2015-08-31
RS57323B1 (en) 2018-08-31
SG182614A1 (en) 2012-08-30
HRP20180855T1 (en) 2018-06-29
ME03058B (en) 2019-01-20
FR18C1043I2 (en) 2019-10-11
EP2932970A1 (en) 2015-10-21
US20160339033A1 (en) 2016-11-24
LT3494972T (en) 2024-03-12
HUE026849T2 (en) 2016-08-29
TR201807704T4 (en) 2018-06-21
US20120295898A1 (en) 2012-11-22
US20180200254A1 (en) 2018-07-19
EA201690872A2 (en) 2016-08-31
IL245182A0 (en) 2016-06-30
KR20160111536A (en) 2016-09-26
NZ601319A (en) 2014-08-29
DK2531027T3 (en) 2015-07-20
CN105311033A (en) 2016-02-10
CY1116509T1 (en) 2017-03-15
MX367938B (en) 2019-09-12
CA2967453A1 (en) 2011-08-04
PH12016500195B1 (en) 2016-12-05
US20210401850A1 (en) 2021-12-30
CA3003988C (en) 2020-01-07
FI3494972T3 (en) 2024-03-01
EA025176B1 (en) 2016-11-30
EP3127542B1 (en) 2018-08-22
HUS2400017I1 (en) 2024-06-28
UA105556C2 (en) 2014-05-26
PE20121524A1 (en) 2012-12-03
CY1120457T1 (en) 2019-07-10
RS65183B1 (en) 2024-03-29
PH12018502489A1 (en) 2020-06-15
US20170079982A1 (en) 2017-03-23
CO6602152A2 (en) 2013-01-18
JP2021091705A (en) 2021-06-17
EP3494972B1 (en) 2023-12-13
RS57728B1 (en) 2018-12-31
MA34002B1 (en) 2013-02-01
PT3127542T (en) 2018-11-26
KR101883750B1 (en) 2018-07-31
CA2967453C (en) 2018-07-17
EA202190473A3 (en) 2021-12-31
PH12016500195A1 (en) 2016-12-05
IL245182B (en) 2018-04-30
CA2787691A1 (en) 2011-08-04
DOP2021000147A (en) 2022-01-16
EA201290583A1 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
CL2012002080A1 (en) A combination comprising (4r, 12as) -n- [2,4-fluoro-phenyl) -methyl] -3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6.8 -dioxo-2h-pyrido- {1 ', 2': 4,5] -pyrazino- [2,1-b] [1,3] -oxazin-9-carboxamide (gsk1349572) and one or more of the group: abacavir , efavirenz and lopinavir, may additionally contain lamivudine, useful for the treatment of hiv.
CL2008003405A1 (en) Compounds derived from thienopyridine, inhibitors of the hiv integrase enzyme; pharmaceutical composition comprising said compounds; and its use to treat an HIV infection.
CL2015001864A1 (en) Compounds derived from substituted spiropyrido [1,2-a] pyrazine, as hiv integrase inhibitors; pharmaceutical composition that includes them; and its use for the prophylaxis or treatment of a hiv infection.
CL2013001339A1 (en) Condensed heterocyclic derivative compounds, with antiviral activity; pharmaceutical composition that includes them; and its use for the prevention or treatment of HIV infection.
CL2013001338A1 (en) Compounds derived from substituted benzothiene-pyridines, hiv replication inhibitors; pharmaceutical composition that includes them; pharmaceutical combination; pharmaceutical kit; and its use for the treatment of hiv.
CL2012002355A1 (en) Compounds derived from 1,3,4,8-tetrahydro-2h-pyrido [1,2-a] pyrazine; pharmaceutical composition that includes them; pharmaceutical kit; and its use as hiv integrase inhibitors for the treatment of an infectious hiv disease.
CL2013003019A1 (en) Compounds derived from benzothiazole; pharmaceutical composition that includes them; and its use in the treatment of hiv.
CL2015001756A1 (en) Compounds derived from polycyclic carbamoylpyridone; pharmaceutical composition that includes them; and its use for the treatment of a hiv infection in a human who has or is at risk of having the infection.
CL2008003406A1 (en) Quinoline derived compounds; pharmaceutical composition comprising them; and use in the treatment of an HIV infection.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
CL2013003145A1 (en) Pharmaceutical formulation comprising mixture of anti-alpha4 beta7 antibody, an antioxidant or chelator and at least one free amino acid.
CL2012002771A1 (en) Compounds of substituted aryletinyl, modulators of mglur5 receptors; obtaining process; pharmaceutical composition; and its use in the treatment or prevention of schizophrenia, cognitive diseases, x fragile syndrome or autism.
CL2007003565A1 (en) COMPOUNDS DERIVED FROM REPLACED PIPERIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT AN HIV INFECTION.
CR20140200A (en) SOLID FORMS OF 3- (5-AMINO-2-METHYL-4-OXO-AH-QUINAZOLIN-3-IL) -PIPERIDIN-2,6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND THEIR USES
CL2012003421A1 (en) Compounds derived from 3-amino-n- (4-carbamoylpyridin-3-yl) (aryl / heteroaryl) -2-carboxamide; preparation procedure; pharmaceutical composition that includes them; and its use in the treatment of a disease of the snc, oncological, among others. pct national phase
CL2008003593A1 (en) Isoxazolo-pyridazine derived compounds; preparation procedure; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cognitive disorders such as Alzheimer's
CL2007003686A1 (en) COMPOUNDS DERIVED FROM INDOL WITH UNITED RING IN POSITIONS 4,5; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND TO TREAT A VIRAL INFECTION.
CL2012001959A1 (en) Compounds derived from thiophene-2-carboxylic acid, flaviviridae virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment of a viral infection by flaviviridae.
EA201270590A1 (en) ACTIVE INHIBITORS
BR112013025777A2 (en) imidazopyridazines as akt kinase inhibitors
CL2008002708A1 (en) COMPOUNDS DERIVED FROM AZACICLILISOQUINOLINONA AND ISOINDOLINONA, HISTAMINE-3 ANTAGONISTS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND USE OF THE COMPOUND FOR THE TREATMENT OF A COGNITIVE DISORDER,
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
CL2013000881A1 (en) Pharmaceutical combinations comprising a component (a) corresponding to compounds derived from omega-carboxy-substituted-diphenylurea, (b) compounds derived from n- (2-arylamino) arylsulfonamide and (c) which are one or more additional pharmaceutical agents; and its use in the treatment of cancer
CL2014000393A1 (en) Compounds derived from benzofuran and its salts, as hepatitis c virus inhibitors; pharmaceutical composition that includes them; and its use for the treatment or prevention of an infection with the hepatitis c virus or a disease associated with said infection.